RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nabriva Therapeutics Stock

Nabriva Therapeutics ROCE 2024

Nabriva Therapeutics ROCE

-15.54

Ticker

NBRV

ISIN

IE00BL53QQ85

WKN

A2QKWR

In 2024, Nabriva Therapeutics's return on capital employed (ROCE) was -15.54, a 1,608.41% increase from the -0.91 ROCE in the previous year.

Nabriva Therapeutics Aktienanalyse

What does Nabriva Therapeutics do?

Nabriva Therapeutics PLC is a biopharmaceutical company based in Dublin that focuses on the research, development, and marketing of antibiotics for medical needs. The company was founded in 2006 and has since become the leading provider of antibiotics for infectious diseases in Europe and the USA. Nabriva Therapeutics' business model aims to improve the production of antibiotics for acute infections and develop innovative drugs for use in clinical practice and emergency settings. It specializes in serious and life-threatening infections such as pneumonia, bacterial skin and soft tissue infections, and bacterial infections of the urinary tract. The company is divided into two business segments: antibody therapeutics and antibiotics. Antibody therapeutics stimulate the body's immune system to better fight pathogens, while antibiotics directly combat and inhibit the growth of bacteria. Nabriva Therapeutics' flagship product is the antibiotic Xenleta (Levofloxacin) for the treatment of pneumonia. Xenleta is a bactericidal antibiotic that is effective against a variety of difficult-to-treat pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus with reduced susceptibility to Vancomycin (VSSA), acting directly on bacteria. It has been reviewed and approved by the FDA. Nabriva Therapeutics has also advanced the development of Contepo (Fosfomycin) in the field of antibiotics. Contepo is a broad-spectrum antibiotic that is effective against gram-positive and gram-negative bacteria and is intended for the treatment of infectious diseases of the urinary tract. Nabriva Therapeutics has submitted a support application to the FDA for the approval of Contepo for the therapy of complicated urinary tract infections. In August 2020, Nabriva Therapeutics announced the completion of an agreement with Taiho Pharmaceutical Co., Ltd. to market Xenleta in Brazil. The company has also entered into a collaboration with Merck and Co.'s biopharmaceutical organization to investigate the potential of Xenleta for treating patients with diseases such as bacterial skin and soft tissue infections and lung infections. Overall, Nabriva Therapeutics has played an important role in the development of antibiotics for infectious diseases and the fight against antibiotic resistance. With its innovative products and collaboration with other biopharmaceutical organizations, Nabriva Therapeutics has improved its position in the industry and strengthened its leadership in the field of antibiotic therapy. Nabriva Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Nabriva Therapeutics's Return on Capital Employed (ROCE)

Nabriva Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Nabriva Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Nabriva Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Nabriva Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Nabriva Therapeutics stock

What is the ROCE (Return on Capital Employed) of Nabriva Therapeutics this year?

The ROCE of Nabriva Therapeutics is -15.54 undefined this year.

How has the ROCE (Return on Capital Employed) of Nabriva Therapeutics developed compared to the previous year?

The ROCE of Nabriva Therapeutics has increased by 1,608.41% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Nabriva Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Nabriva Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Nabriva Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Nabriva Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Nabriva Therapeutics impact the company?

An increase in the ROCE of Nabriva Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Nabriva Therapeutics affect the company?

A decrease in ROCE of Nabriva Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Nabriva Therapeutics?

Some factors that can affect Nabriva Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Nabriva Therapeutics so important for investors?

The ROCE of Nabriva Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Nabriva Therapeutics take to improve the ROCE?

To improve the ROCE, Nabriva Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Nabriva Therapeutics pay?

Over the past 12 months, Nabriva Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nabriva Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Nabriva Therapeutics?

The current dividend yield of Nabriva Therapeutics is .

When does Nabriva Therapeutics pay dividends?

Nabriva Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nabriva Therapeutics?

Nabriva Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Nabriva Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nabriva Therapeutics located?

Nabriva Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nabriva Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nabriva Therapeutics from 7/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.

When did Nabriva Therapeutics pay the last dividend?

The last dividend was paid out on 7/31/2024.

What was the dividend of Nabriva Therapeutics in the year 2023?

In the year 2023, Nabriva Therapeutics distributed 0 USD as dividends.

In which currency does Nabriva Therapeutics pay out the dividend?

The dividends of Nabriva Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nabriva Therapeutics

Our stock analysis for Nabriva Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nabriva Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.